Despite promising research: Novo Nordisk will not test semaglutide in hip patients
The company has no plans to test the molecule’s effect on hip replacement - a patient group for which a study with semaglutide has shown promise.
Novo Nordisk’s fast-growing super-seller is in such high demand that production can’t keep up, and recently, new trial results indicate that the molecule behind Novo Nordisk’s success, semaglutide, may even have long-term potential in connection with hip surgery.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
